Mirum Pharmaceuticals (MIRM)
(Delayed Data from NSDQ)
$51.84 USD
-0.40 (-0.77%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $51.84 0.00 (0.00%) 7:40 PM ET
3-Hold of 5 3
D Value A Growth C Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
MIRM 51.84 -0.40(-0.77%)
Will MIRM be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MIRM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MIRM
Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates
Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
MIRM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Mirum Gains 35% in 3 Months: How Should You Play the Stock?
EMA Accepts GSK's Filing for Linerixibat in Rare Disease-Related Itch
Why Is Editas (EDIT) Up 40% Since Last Earnings Report?
Other News for MIRM
ClearBridge Small Cap Growth Portfolios Q2 2025 Commentary
ClearBridge Small Cap Growth Fund Q2 2025 Commentary
Mirum Pharmaceuticals Inc (MIRM) Announces Upcoming Second Quarter 2025 Financial Results | ...
Mirum Pharmaceuticals (MIRM) Sees Price Target Uplift from Evercore ISI | MIRM Stock News
Mirum Pharmaceuticals price target raised by $8 at Evercore ISI, here's why